Date: Tuesday 3rd February 2026 Time: 14:00 - 15:00 GMT | 9:00 - 10:00 EST (US) Location: Online via Zoom Speakers: Weiliang Qiu (Sanofi)
Who is this event intended for?: Statisticians and Scientists involved or interested in Multi-Group Comparison of Means for Single-Factor Experiment with Small Sample Size Under Normality and Heteroscedasticity.
What is the benefit of attending?: Be able to choose the most appropriate method on Heteroscedastic data
Cost
This webinar is free to both Members of PSI and Non-Members.
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Speaker details
Speaker
Biography
Abstract
Weiliang Qiu, Sanofi
Weiliang Qiu is a Non-Clinical Efficacy and Safety Statistician Expert Leader at Sanofi, passionate about leveraging statistical expertise to improve patients’ lives. He earned his Ph.D. in Statistics from the University of British Columbia in 2004 and spent 14 years at Brigham and Women’s Hospital/Harvard Medical School, contributing to impactful research.
Since joining Sanofi’s Non-Clinical Efficacy and Safety (NCES) team in 2018, Weiliang has provided statistical support for non-clinical studies across diverse therapeutic areas, including translational sciences, rare and neurological diseases, immunology and inflammation, immuno-oncology, and gene therapy. In addition to supporting these studies, he collaborates closely with teammates in NCES to design and implement innovative statistical methodologies that enhance data analysis and drive scientific insights.
Modern Algorithms for Animal Randomization in Preclinical Studies
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Scientific Meetings
Pre-Clinical SIG Webinar: Multi-Group Comparison of Means for Single-Factor Experiment with Small Sample Size Under Normality and Heteroscedasticity
Date: Tuesday 3rd February 2026 Time: 14:00 - 15:00 GMT | 9:00 - 10:00 EST (US) Location: Online via Zoom Speakers: Weiliang Qiu (Sanofi)
Who is this event intended for?: Statisticians and Scientists involved or interested in Multi-Group Comparison of Means for Single-Factor Experiment with Small Sample Size Under Normality and Heteroscedasticity.
What is the benefit of attending?: Be able to choose the most appropriate method on Heteroscedastic data
Cost
This webinar is free to both Members of PSI and Non-Members.
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Speaker details
Speaker
Biography
Abstract
Weiliang Qiu, Sanofi
Weiliang Qiu is a Non-Clinical Efficacy and Safety Statistician Expert Leader at Sanofi, passionate about leveraging statistical expertise to improve patients’ lives. He earned his Ph.D. in Statistics from the University of British Columbia in 2004 and spent 14 years at Brigham and Women’s Hospital/Harvard Medical School, contributing to impactful research.
Since joining Sanofi’s Non-Clinical Efficacy and Safety (NCES) team in 2018, Weiliang has provided statistical support for non-clinical studies across diverse therapeutic areas, including translational sciences, rare and neurological diseases, immunology and inflammation, immuno-oncology, and gene therapy. In addition to supporting these studies, he collaborates closely with teammates in NCES to design and implement innovative statistical methodologies that enhance data analysis and drive scientific insights.
Modern Algorithms for Animal Randomization in Preclinical Studies
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Training Courses
Pre-Clinical SIG Webinar: Multi-Group Comparison of Means for Single-Factor Experiment with Small Sample Size Under Normality and Heteroscedasticity
Date: Tuesday 3rd February 2026 Time: 14:00 - 15:00 GMT | 9:00 - 10:00 EST (US) Location: Online via Zoom Speakers: Weiliang Qiu (Sanofi)
Who is this event intended for?: Statisticians and Scientists involved or interested in Multi-Group Comparison of Means for Single-Factor Experiment with Small Sample Size Under Normality and Heteroscedasticity.
What is the benefit of attending?: Be able to choose the most appropriate method on Heteroscedastic data
Cost
This webinar is free to both Members of PSI and Non-Members.
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Speaker details
Speaker
Biography
Abstract
Weiliang Qiu, Sanofi
Weiliang Qiu is a Non-Clinical Efficacy and Safety Statistician Expert Leader at Sanofi, passionate about leveraging statistical expertise to improve patients’ lives. He earned his Ph.D. in Statistics from the University of British Columbia in 2004 and spent 14 years at Brigham and Women’s Hospital/Harvard Medical School, contributing to impactful research.
Since joining Sanofi’s Non-Clinical Efficacy and Safety (NCES) team in 2018, Weiliang has provided statistical support for non-clinical studies across diverse therapeutic areas, including translational sciences, rare and neurological diseases, immunology and inflammation, immuno-oncology, and gene therapy. In addition to supporting these studies, he collaborates closely with teammates in NCES to design and implement innovative statistical methodologies that enhance data analysis and drive scientific insights.
Modern Algorithms for Animal Randomization in Preclinical Studies
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Journal Club
Pre-Clinical SIG Webinar: Multi-Group Comparison of Means for Single-Factor Experiment with Small Sample Size Under Normality and Heteroscedasticity
Date: Tuesday 3rd February 2026 Time: 14:00 - 15:00 GMT | 9:00 - 10:00 EST (US) Location: Online via Zoom Speakers: Weiliang Qiu (Sanofi)
Who is this event intended for?: Statisticians and Scientists involved or interested in Multi-Group Comparison of Means for Single-Factor Experiment with Small Sample Size Under Normality and Heteroscedasticity.
What is the benefit of attending?: Be able to choose the most appropriate method on Heteroscedastic data
Cost
This webinar is free to both Members of PSI and Non-Members.
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Speaker details
Speaker
Biography
Abstract
Weiliang Qiu, Sanofi
Weiliang Qiu is a Non-Clinical Efficacy and Safety Statistician Expert Leader at Sanofi, passionate about leveraging statistical expertise to improve patients’ lives. He earned his Ph.D. in Statistics from the University of British Columbia in 2004 and spent 14 years at Brigham and Women’s Hospital/Harvard Medical School, contributing to impactful research.
Since joining Sanofi’s Non-Clinical Efficacy and Safety (NCES) team in 2018, Weiliang has provided statistical support for non-clinical studies across diverse therapeutic areas, including translational sciences, rare and neurological diseases, immunology and inflammation, immuno-oncology, and gene therapy. In addition to supporting these studies, he collaborates closely with teammates in NCES to design and implement innovative statistical methodologies that enhance data analysis and drive scientific insights.
Modern Algorithms for Animal Randomization in Preclinical Studies
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Webinars
Pre-Clinical SIG Webinar: Multi-Group Comparison of Means for Single-Factor Experiment with Small Sample Size Under Normality and Heteroscedasticity
Date: Tuesday 3rd February 2026 Time: 14:00 - 15:00 GMT | 9:00 - 10:00 EST (US) Location: Online via Zoom Speakers: Weiliang Qiu (Sanofi)
Who is this event intended for?: Statisticians and Scientists involved or interested in Multi-Group Comparison of Means for Single-Factor Experiment with Small Sample Size Under Normality and Heteroscedasticity.
What is the benefit of attending?: Be able to choose the most appropriate method on Heteroscedastic data
Cost
This webinar is free to both Members of PSI and Non-Members.
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Speaker details
Speaker
Biography
Abstract
Weiliang Qiu, Sanofi
Weiliang Qiu is a Non-Clinical Efficacy and Safety Statistician Expert Leader at Sanofi, passionate about leveraging statistical expertise to improve patients’ lives. He earned his Ph.D. in Statistics from the University of British Columbia in 2004 and spent 14 years at Brigham and Women’s Hospital/Harvard Medical School, contributing to impactful research.
Since joining Sanofi’s Non-Clinical Efficacy and Safety (NCES) team in 2018, Weiliang has provided statistical support for non-clinical studies across diverse therapeutic areas, including translational sciences, rare and neurological diseases, immunology and inflammation, immuno-oncology, and gene therapy. In addition to supporting these studies, he collaborates closely with teammates in NCES to design and implement innovative statistical methodologies that enhance data analysis and drive scientific insights.
Modern Algorithms for Animal Randomization in Preclinical Studies
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Careers Meetings
Pre-Clinical SIG Webinar: Multi-Group Comparison of Means for Single-Factor Experiment with Small Sample Size Under Normality and Heteroscedasticity
Date: Tuesday 3rd February 2026 Time: 14:00 - 15:00 GMT | 9:00 - 10:00 EST (US) Location: Online via Zoom Speakers: Weiliang Qiu (Sanofi)
Who is this event intended for?: Statisticians and Scientists involved or interested in Multi-Group Comparison of Means for Single-Factor Experiment with Small Sample Size Under Normality and Heteroscedasticity.
What is the benefit of attending?: Be able to choose the most appropriate method on Heteroscedastic data
Cost
This webinar is free to both Members of PSI and Non-Members.
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Speaker details
Speaker
Biography
Abstract
Weiliang Qiu, Sanofi
Weiliang Qiu is a Non-Clinical Efficacy and Safety Statistician Expert Leader at Sanofi, passionate about leveraging statistical expertise to improve patients’ lives. He earned his Ph.D. in Statistics from the University of British Columbia in 2004 and spent 14 years at Brigham and Women’s Hospital/Harvard Medical School, contributing to impactful research.
Since joining Sanofi’s Non-Clinical Efficacy and Safety (NCES) team in 2018, Weiliang has provided statistical support for non-clinical studies across diverse therapeutic areas, including translational sciences, rare and neurological diseases, immunology and inflammation, immuno-oncology, and gene therapy. In addition to supporting these studies, he collaborates closely with teammates in NCES to design and implement innovative statistical methodologies that enhance data analysis and drive scientific insights.
Modern Algorithms for Animal Randomization in Preclinical Studies
The design of single-factor experiment is commonly used to compare multiple groups in non-clinical studies, where group sizes are generally small and groups usually have different variances. The classical F test tends to inflate type I error rate in this scenario. Many alternative tests have been proposed in literature to manage heterogeneity of variance. Several papers compared these alternative tests, among which is heterogeneous-variance mixed-effects model using Satterthwaite approximation of degree of freedom. The mixed-effects model approach has at least 2 advantages over other tests: (1) allowing different group variance structures (e.g., homogeneous-variance or heterogeneous-variance); and (2) the capacity to do model diagnosis via residual analysis. In this presentation, we evaluate both Type I error rates and powers of the 13 tests investigated in Pham et al. (2020) spanning ANOVA-based tests, structured means modeling (SMM), and mixed-effects models—under diverse conditions, including (un)equal variances, (non-)normal distributions, and (un)balanced designs. Two additional mixed-effects models (homogeneous-variance mixed-effects model and adaptive mixed-effects model) are introduced and assessed alongside the 13 tests. We also consider the Kenward-Roger approximation of degrees of freedom for the 3 mixed-effects models, which generally offers more reliable type I error rate than the Satterthwaite approximation. Some recommendations about analysis for data from single-factor experiments will finally be given.
Upcoming Events
PSI Introduction to Industry Training (ITIT) Course - 2026/2027
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Join our Health Technology Assessment (HTA) European Special Interest Group (ESIG) for a webinar on the strategic role of statisticians in the Joint Clinical Assessment (JCA). The introduction of the JCA marks a new era for evidence generation and market access in Europe. As HTA requirements become more harmonized and methodologically demanding, the role of statisticians has evolved far beyond data analysis. Today, statistical expertise is central to shaping clinical development strategies, designing robust comparative evidence, and ensuring that submissions withstand the scrutiny of EU-level assessors. In this webinar, we explore how statisticians contribute strategically to successful JCA outcomes.
Statisticians in the Age of AI: On Route to Strategic Partnership
A 90-minute webinar featuring two case studies from Bayer and Roche demonstrating how statisticians successfully integrated into AI programs, followed by interactive discussion on strategies for elevating statistical expertise in the AI era.
Our monthly webinar series allows attendees to gain practical knowledge and skills in open-source coding and tools, with a focus on applications in the pharmaceutical industry. This month’s session, “Graphics Basics,” will introduce the fundamentals of producing graphics using the ggplot2 package.
Enhancing Clinical Study Reporting with the Estimand Framework
Join us for an insightful webinar where we explore practical strategies for applying the estimand framework in clinical study reporting. Drawing on real-world experiences and case studies, we will share recommendations to help you:
• Understand the role of estimands in improving transparency and interpretation of trial results.
• Navigate common challenges in implementing the framework during reporting.
• Apply best practices to enhance regulatory submissions, webposting in public registries (clinicaltrials.gov/CTIS), and scientific publications.
Whether you are involved in clinical trial design, data analysis, or regulatory submissions, this session will provide actionable guidance to realize the full potential of the estimand framework.
The Book Club session will discuss a podcast episode where the host of the Power Hour, Adrienne Herbert, chats with Ros about his book, and the secrets that he learned from years of working in high-pressure newsrooms, and the ten elements of a good explanation and the seven steps you need to take to express yourself with clarity and impact.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Book Club: The AI Con – Joint with ASA Book Club
The Guardian described the authors of this book as refreshingly sarcastic! What is sold to us as AI, they announce, is just "a bill of goods": "A few major well-placed players are poised to accumulate significant wealth by extracting value from other people's creative work, personal data, or labour, and replacing quality services with artificial facsimiles."
PSI Book Club: Another Door Opens – Book Club Special Event
This is a Book Club Special Event in response to the changes in our industry and as a supportive move to create community and connection for those navigating redundancy and uncertainty. Read the book in advance of the book club session then join the zoom call to discuss ideas. There will be breakout groups to connect with others, exchange experiences of how the book has helped, and offer support.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
GSK - Statistics Director - Vaccines and Infectious Disease
We are seeking an experienced and visionary Statistics Director to join our Team and lead strategic statistical innovation across GSK’s Vaccines and Infectious Disease portfolio.
As a Senior Biostatistician I at ICON, you will play a pivotal role in designing and analyzing clinical trials, interpreting complex medical data, and contributing to the advancement of innovative treatments and therapies.
As a Statistical Programmer II at ICON, you will play a vital role in the development, validation, and execution of statistical programs to support clinical trial analysis and reporting.
As a Statistical Scientist at ICON, you will play a pivotal role in designing and analyzing clinical trials, interpreting complex medical data, and contributing to the advancement of innovative treatments and therapies.
We have an exciting opportunity for an Associate Director, Biostatistics to join a passionate team within Advanced Quantitative Sciences – Full Development.
: We have an exciting opportunity for an Associate Director (AD), Statistical Programming, to join a passionate team within Advanced Quantitative Sciences- Development.
Novartis - Senior Principal Statistical Programmer
We have an exciting opportunity for a Senior Principal Statistical Programmer, to join a passionate team within Advanced Quantitative Sciences – Development.
Pierre Fabre - Clinical Development Safety Statistics Expert M/F
We are seeking a highly skilled and proactive Clinical Development Safety Statistics Expert to join our Biometry Department and the Biometry Leadership Team based in Toulouse (31, Oncopole) or Boulogne (92).
Pierre Fabre - Lead Statistician – Real World Evidence -CDI- M/F
Pierre Fabre Laboratories are hiring a highly skilled and experienced Lead Statistician – Real World Evidence (RWE) to join the Biometry Department, part of the Data Science & Biometry Department, based in Toulouse (Oncopôle) or Boulogne.
Pierre Fabre - Lead Statistician- Clinical Trials M/F
We are seeking a highly skilled and experienced Lead Statistician in Clinical Trials to join our Biometry Department based in Toulouse (31, Oncopole) or Boulogne (92).
As a Senior Statistician at Viatris, you will take a leading role in designing clinical studies, guiding statistical strategy, and ensuring that statistical deliverables meet the highest scientific and regulatory standards.